Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

The Trem2 R47H variant confers loss-of-function-like phenotypes in Alzheimer's disease.

Cheng-Hathaway PJ, Reed-Geaghan EG, Jay TR, Casali BT, Bemiller SM, Puntambekar SS, von Saucken VE, Williams RY, Karlo JC, Moutinho M, Xu G, Ransohoff RM, Lamb BT, Landreth GE.

Mol Neurodegener. 2018 Jun 1;13(1):29. doi: 10.1186/s13024-018-0262-8.

2.
3.

Aβ Extraction from Murine Brain Homogenates.

Casali BT, Landreth GE.

Bio Protoc. 2016 Apr 20;6(8). pii: e1787. doi: 10.21769/BioProtoc.1787.

4.

ABCA1 is Necessary for Bexarotene-Mediated Clearance of Soluble Amyloid Beta from the Hippocampus of APP/PS1 Mice.

Corona AW, Kodoma N, Casali BT, Landreth GE.

J Neuroimmune Pharmacol. 2016 Mar;11(1):61-72. doi: 10.1007/s11481-015-9627-8. Epub 2015 Jul 15.

PMID:
26175148
5.

Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor γ Agonist Treatment Reduces Amyloid β Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 Mice.

Skerrett R, Pellegrino MP, Casali BT, Taraboanta L, Landreth GE.

J Biol Chem. 2015 Aug 28;290(35):21591-602. doi: 10.1074/jbc.M115.652008. Epub 2015 Jul 10.

6.

Omega-3 Fatty Acids Augment the Actions of Nuclear Receptor Agonists in a Mouse Model of Alzheimer's Disease.

Casali BT, Corona AW, Mariani MM, Karlo JC, Ghosal K, Landreth GE.

J Neurosci. 2015 Jun 17;35(24):9173-81. doi: 10.1523/JNEUROSCI.1000-15.2015.

7.

ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models.

Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, Brunden KR, Wilson DA, Landreth GE.

Science. 2012 Mar 23;335(6075):1503-6. doi: 10.1126/science.1217697. Epub 2012 Feb 9.

Supplemental Content

Loading ...
Support Center